Enliven insider plans sale of 48,300 shares

Enliven Therapeutics insider Anish Patel has filed a notice to sell common stock under Rule 144.

Rhea-AI Filing Summary

Enliven Therapeutics insider Anish Patel has filed a notice to sell common stock under Rule 144. The filing covers 48,300 common shares to be sold through Jefferies LLC on or about 01/09/2026 on the Nasdaq market, with an aggregate market value of $1,122,975.00. The filing notes 59,000,000 shares of the issuer’s stock outstanding.

The shares to be sold are founder shares of common stock acquired from Enliven Therapeutics on 09/01/2019. Over the past three months, Patel has already sold 6,667 shares for gross proceeds of $116,034.33 on 11/07/2025 and 6,663 shares for gross proceeds of $140,072.92 on 12/08/2025. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ELVN disclose?

The filing discloses that Anish Patel plans to sell 48,300 common shares of Enliven Therapeutics under Rule 144, using Jefferies LLC as broker on or about 01/09/2026 on the Nasdaq.

How many Enliven Therapeutics (ELVN) shares has Anish Patel recently sold?

Over the past three months, Anish Patel sold 6,667 shares on 11/07/2025 for $116,034.33 and 6,663 shares on 12/08/2025 for $140,072.92 in gross proceeds.

What is the value of the ELVN shares Anish Patel plans to sell?

The planned sale under Rule 144 covers 48,300 common shares of Enliven Therapeutics with an aggregate market value of $1,122,975.00, as stated in the notice.

How many Enliven Therapeutics shares are outstanding according to this filing?

The notice states that 59,000,000 shares of Enliven Therapeutics common stock are outstanding.

When and how did Anish Patel acquire the ELVN shares being sold?

The shares being sold are founder shares of common stock acquired from Enliven Therapeutics on 09/01/2019, with the payment date listed as the same day.

What representation does the seller make in this ELVN Form 144?

By signing the notice, the seller represents that he does not know any material adverse information about Enliven Therapeutics’ current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 04:18 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001967163
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Patel Anish
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	48300	1122975.00	59000000	01/09/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder Shares	Enliven Therapeutics			48300	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Anish Patel 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics	11/07/2025	6667	116034.33
Anish Patel 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics	12/08/2025	6663	140072.92

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 9/30/2024, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold by The Patel/Dong Family Trust UAD 08/24/17.
Date of Notice	01/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/30/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Anish Patel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)